Exploring pulegone in type 2 diabetes treatment: Molecular docking, influence on insulin resistance and modulation of pro/anti-inflammatory cytokines
Abstract
BACKGROUND: Type 2 diabetes involves insulin resistance, where muscle, liver, and fat cells fail to utilize glucose leading to hyperglycemia.
OBJECTIVES: This study explores the therapeutic potential of pulegone in type 2 diabetes by examining its molecular interactions with key metabolic targets and evaluating its effects on insulin resistance and inflammatory cytokine modulation.
METHODS: Except for normal controls, animals were fed a high-sucrose, high-fat diet for four months to induce insulin resistance. Treatment groups received metformin (150 mg/kg) or pulegone doses: low (5 mg/kg), medium (10 mg/kg), and high (15 mg/kg) for 45 days. Post-treatment, tissues and blood were collected. Blood serum was analyzed for liver markers, lipid profile, and blood for glycated hemoglobin. ELISA was used for cytokines (resistin, adiponectin, IL-1Ra, TNF-α), and qPCR assessed gene expression of NF-κB, TNF-α, PPAR-α/γ, IL-6, IL-10, IL-1Ra, and adiponectin. Histopathology was performed. Data were analyzed using GraphPad Prism. Molecular docking was conducted to identify the binding affinities of pulegone to target proteins.
RESULTS: Pulegone significantly reduced fasting blood glucose, glycated hemoglobin, triglycerides, cholesterol, and liver enzymes, while increasing HDL levels compared with diabetic controls. It also decreased serum resistin, TNF-α, IL-6 and NF-κB expression, while upregulating adiponectin, IL-10, PPAR-α, PPAR-γ and IL-1Ra. Histopathological examination showed…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.